Metabolism Disorder TRIZ Cases

Engineered microbial lysozymes stabilize gut microbiota and suppress bacterial pathogens.

Grafts immature canine pancreas into scid mice to generate functional beta cell lines, solving the limited expandability of cryopreserved islets.

Combining MIC-1 with GLP-1 overcomes short half-life limits, reducing daily dosing frequency.

Abelmoschus esculentus ferment inhibits amylase and glucosidase to reduce starch absorption.

Enzymatically formed glycosyl linkers attach polymeric modifying groups to peptides, reducing antigenicity and improving stability.

B24 cyclohexanylalanine substitution accelerates hexamer disassembly to improve glycemic control while maintaining thermal stability against fibrillation.

OEG spacer agents enable selective peptide acylation, reducing impurities and purification costs.

A biological oil composition derived from Calanus finmarchicus copepods utilizes specific wax esters and stearidonic acid to inhibit plaque formation.

Optimized linker peptide between GLP-1 and HSA improves protease resistance and in-vivo half-life, reducing immunogenicity risks.

A nutritional product containing specific amounts of protein and vitamin D increases insulin sensitivity in overweight adults.

Antibodies neutralize angiopoietin-like 4 protein to restore lipoprotein lipase activity and reduce elevated plasma triglycerides.

MC4R agonists activate signaling pathways in heterozygous carriers, resolving unresponsiveness to traditional treatments.

Vacuum drying PQQ acid produces crystal form B, eliminating hygroscopicity and irregular morphology for reliable drug processing.

Placental mesenchymal stem cell conditioned medium containing IL-6 and MCP-1 treats preeclampsia by reducing TNF-alpha inflammation.

Modified peptides resist DPP-IV degradation to extend half-life while reducing beta-arrestin signaling and nausea side effects.

A citrus polyphenol composition stimulates lipolysis through flavonoid and anthocyanin synergy.

Soluble microneedle composition combines semaglutide and hyaluronidase to facilitate systemic diffusion, resolving low bioavailability of large molecules.

Plant secondary metabolites in multivitamins target specific microRNAs to modify gene expression, addressing insufficient efficacy of classic supplements.

Targeted PEG modification at lysine 27 resolves the trade-off between extended duration and reduced biological activity.

Asymmetric boronate scaffolds orient hydroxyl groups to selectively bind glucose while reducing affinity for other sugars.

GGL tripeptide compositions stimulate insulin secretion to manage blood glucose levels while reducing cardiovascular risks associated with diabetes treatments.

Segmented coating protects sensitive ingredients from gastric acid while enzymatic digestion triggers targeted intestinal release for reliable bioavailability.

Chemically modified lectins reduce mitogenicity while maintaining glucose responsiveness for safer insulin delivery.

A super fast-acting insulin composition combines a fast-acting analog with hyaluronan degrading enzyme to accelerate systemic absorption.

Zinc binds to fucoidan sulfate groups to overcome limited intestinal uptake, boosting anti-ulcer and antitumor activity levels.

A pharmaceutical composition combining PDE5 inhibitors with branched-chain amino acids to regulate energy metabolism pathways.

CD24 protein mediates endogenous leptin production, avoiding neutralizing antibodies and frequent dosing required by direct replacement therapy.

A composition of guarana and ginkgo biloba isolates with fruit sugars enhances vigilance without affecting heart activity.

Alkyl ether bonds stabilize liposomes against suspension instability while enabling targeted delivery of therapeutic agents.

A long-acting insulin analog conjugate extends in vivo duration through targeted amino acid substitutions and biocompatible polymer linking.

Modified peptide structure resists DPP IV degradation to extend duration of action for diabetes treatment.

A heterocyclic compound binds to the Skp2 protein component of the ubiquitin ligase complex.

A dipeptide medical preparation suppresses HIF-1α synthesis to enhance tissue oxygenation in diabetic foot conditions.

Plant extracts normalize lipid metabolism by increasing LDL receptor expression, resolving the trade-off between cholesterol control and quality of life.

Preliminary dry co-grinding at 50°C resolves extrusion degradation of high-content hydrophilic active principles.

Saturated fat coating enables ruminal bypass of non-protein nitrogen compounds, reducing ammonia toxicity while enhancing nitrogen utilization.

Antibodies targeting FSH receptors decrease visceral fat accumulation while managing reproductive function trade-offs.

Recombinant AAV vectors deliver functional genes to restore adipose tissue, reducing insulin resistance and hepatomegaly.

Mitochondria-targeted cations accumulate in organelles to increase proton permeability via fatty acid complexes.

Emulsified thyme and cinnamon oil blends replace antibiotics to boost growth rates while preventing pathogenic resistance.

A prodrug formulation links exendin to a hydrogel polymer via an amide bond for sustained release.

Ertugliflozin blocks renal glucose reabsorption to treat metabolic disorders in renal impairment while preventing neuronal damage after ischemic stroke.

Antibodies targeting oxidized LDL epitopes induce regression of pre-existing atherosclerotic plaques, reducing plaque burden and increasing vascular lumen.

Variant phenylalanine hydroxylase polypeptides with specific amino acid substitutions enhance enzyme bioactivity and expression levels.

An insulin analog conjugated to an immunoglobulin Fc region via a non-peptidyl linker extends blood circulation time.

Targeted mutations reduce intermolecular clustering to enable high-concentration subcutaneous injection.

Administers GLP-1 agonists alongside anti-IL-21 inhibitors to delay beta-cell destruction and reduce exogenous insulin dependence.